Wiki-Pi

Search Results for: Diabetes

3097 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
BNIP3L and CAMK1D BCL2/adenovirus E1B 19kDa interacting protein 3-like calcium/calmodulin-dependent protein kinase ID
BPGM and CEL 2,3-bisphosphoglycerate mutase carboxyl ester lipase
BRCA1 and MAP3K1 breast cancer 1, early onset mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • FCERI mediated MAPK activation
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activated TLR4 signalling
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll-Like Receptors Cascades
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 10 (TLR10) Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • MyD88 dependent cascade initiated on endosome
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Fc epsilon receptor (FCERI) signaling
  • TRAF6 mediated NF-kB activation
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
BRCA1 and SRC breast cancer 1, early onset SRC proto-oncogene, non-receptor tyrosine kinase
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Signaling by ERBB2
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
BRCA1 and CTCFL breast cancer 1, early onset CCCTC-binding factor (zinc finger protein)-like
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
BRCA1 and GCC1 breast cancer 1, early onset GRIP and coiled-coil domain containing 1
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
BRCA1 and CDK2 breast cancer 1, early onset cyclin-dependent kinase 2
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Activation of the pre-replicative complex
  • Cellular Senescence
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • G2/M Transition
  • p53-Dependent G1/S DNA damage checkpoint
  • Activation of the pre-replicative complex
  • Orc1 removal from chromatin
  • Cyclin E associated events during G1/S transition
  • CDK-mediated phosphorylation and removal of Cdc6
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A/B1 associated events during G2/M transition
  • G2 Phase
  • Activation of ATR in response to replication stress
  • G1/S Transition
  • Removal of licensing factors from origins
  • Mitotic G1-G1/S phases
  • Switching of origins to a post-replicative state
  • G1/S DNA Damage Checkpoints
  • Meiotic recombination
  • DNA Damage/Telomere Stress Induced Senescence
  • Synthesis of DNA
  • DNA Replication Pre-Initiation
  • M/G1 Transition
  • Regulation of DNA replication
  • Senescence-Associated Secretory Phenotype (SASP)
  • G0 and Early G1
  • S Phase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Factors involved in megakaryocyte development and platelet production
  • Cell Cycle, Mitotic
  • APC/C-mediated degradation of cell cycle proteins
  • SCF(Skp2)-mediated degradation of p27/p21
  • Orc1 removal from chromatin
  • Regulation of mitotic cell cycle
  • Cell Cycle Checkpoints
  • SCF(Skp2)-mediated degradation of p27/p21
  • Cyclin A:Cdk2-associated events at S phase entry
  • Mitotic G2-G2/M phases
  • Double Oxidized Cysteine
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Flavopiridol
  • (2e,3s)-3-Hydroxy-5\'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3\'-Biindol-2\'(1\'h)-One
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • Alsterpaullone
  • N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N\'-Hydroxyimidoformamide
  • N\'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4\'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3\'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • (2Z)-5\'-BROMO-2,3\'-BIINDOLE-2\',3(1H,1\'H)-DIONE AMMONIATE
  • (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
  • 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N\',N\'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL
  • (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE
  • N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
  • 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE
  • 3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE
  • 6-CYCLOHEXYLMETHYLOXY-2-(4\'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE
  • 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3\',2\':4,5]pyrrolo[1,2-c]pyrimidin-4-ol
  • N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
BRCA2 and CDK2 breast cancer 2, early onset cyclin-dependent kinase 2
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Activation of the pre-replicative complex
  • Cellular Senescence
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • G2/M Transition
  • p53-Dependent G1/S DNA damage checkpoint
  • Activation of the pre-replicative complex
  • Orc1 removal from chromatin
  • Cyclin E associated events during G1/S transition
  • CDK-mediated phosphorylation and removal of Cdc6
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A/B1 associated events during G2/M transition
  • G2 Phase
  • Activation of ATR in response to replication stress
  • G1/S Transition
  • Removal of licensing factors from origins
  • Mitotic G1-G1/S phases
  • Switching of origins to a post-replicative state
  • G1/S DNA Damage Checkpoints
  • Meiotic recombination
  • DNA Damage/Telomere Stress Induced Senescence
  • Synthesis of DNA
  • DNA Replication Pre-Initiation
  • M/G1 Transition
  • Regulation of DNA replication
  • Senescence-Associated Secretory Phenotype (SASP)
  • G0 and Early G1
  • S Phase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Factors involved in megakaryocyte development and platelet production
  • Cell Cycle, Mitotic
  • APC/C-mediated degradation of cell cycle proteins
  • SCF(Skp2)-mediated degradation of p27/p21
  • Orc1 removal from chromatin
  • Regulation of mitotic cell cycle
  • Cell Cycle Checkpoints
  • SCF(Skp2)-mediated degradation of p27/p21
  • Cyclin A:Cdk2-associated events at S phase entry
  • Mitotic G2-G2/M phases
  • Double Oxidized Cysteine
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Flavopiridol
  • (2e,3s)-3-Hydroxy-5\'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3\'-Biindol-2\'(1\'h)-One
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • Alsterpaullone
  • N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N\'-Hydroxyimidoformamide
  • N\'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4\'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3\'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • (2Z)-5\'-BROMO-2,3\'-BIINDOLE-2\',3(1H,1\'H)-DIONE AMMONIATE
  • (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
  • 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N\',N\'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL
  • (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE
  • N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
  • 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE
  • 3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE
  • 6-CYCLOHEXYLMETHYLOXY-2-(4\'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE
  • 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3\',2\':4,5]pyrrolo[1,2-c]pyrimidin-4-ol
  • N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
BTC and ERBB4 betacellulin erb-b2 receptor tyrosine kinase 4
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • GRB2 events in ERBB2 signaling
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Nuclear signaling by ERBB4
  • SHC1 events in ERBB4 signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
KLF5 and TBP Kruppel-like factor 5 (intestinal) TATA box binding protein
  • Transcriptional regulation of white adipocyte differentiation
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase II Transcription
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Clearance
  • HIV Infection
  • RNA Polymerase II Pre-transcription Events
  • HIV Life Cycle
  • HIV Transcription Initiation
  • NoRC negatively regulates rRNA expression
  • RNA Polymerase II HIV Promoter Escape
  • RNA Polymerase III Transcription Initiation
  • RNA Polymerase III Transcription
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase I Transcription
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase I Promoter Escape
  • Epigenetic regulation of gene expression
  • Negative epigenetic regulation of rRNA expression
  • Late Phase of HIV Life Cycle
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Polymerase III Abortive And Retractive Initiation
  • RNA Polymerase II Transcription Initiation
  • SIRT1 negatively regulates rRNA Expression
  • Transcription of the HIV genome
BTK and SYK Bruton agammaglobulinemia tyrosine kinase spleen tyrosine kinase
  • Signaling by the B Cell Receptor (BCR)
  • DAP12 interactions
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll Like Receptor TLR1:TLR2 Cascade
  • DAP12 signaling
  • Activated TLR4 signalling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • MyD88:Mal cascade initiated on plasma membrane
  • FCERI mediated Ca+2 mobilization
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Regulation of actin dynamics for phagocytic cup formation
  • Adaptive Immune System
  • Innate Immune System
  • Signaling by the B Cell Receptor (BCR)
  • FCERI mediated MAPK activation
  • Platelet Aggregation (Plug Formation)
  • DAP12 signaling
  • Regulation of signaling by CBL
  • Role of phospholipids in phagocytosis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • DAP12 interactions
  • Integrin alphaIIb beta3 signaling
  • Cytokine Signaling in Immune system
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Signaling by Interleukins
  • Fc epsilon receptor (FCERI) signaling
  • GPVI-mediated activation cascade
  • Interleukin-2 signaling
  • FCERI mediated Ca+2 mobilization
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Staurosporine
  • N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
  • 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
  • 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
  • 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
  • Ellagic Acid
C1R and PCK1 complement component 1, r subcomponent phosphoenolpyruvate carboxykinase 1 (soluble)
  • Classical antibody-mediated complement activation
  • Creation of C4 and C2 activators
  • Complement cascade
  • Initial triggering of complement
  • Innate Immune System
  • Gluconeogenesis
  • Glucose metabolism
  • Myoclonic epilepsy of Lafora
  • Transcriptional regulation of white adipocyte differentiation
  • Glycogen storage diseases
  • Metabolism of carbohydrates
  • Abacavir transport and metabolism
  • Abacavir metabolism
  • Phosphoenolpyruvate
  • 1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine
  • 1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine
  • Phosphomethylphosphonic Acid-Guanylate Ester
C3 and LAMA1 complement component 3 laminin, alpha 1
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • Alternative complement activation
  • Class A/1 (Rhodopsin-like receptors)
  • Activation of C3 and C5
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Initial triggering of complement
  • GPCR downstream signaling
  • Peptide ligand-binding receptors
  • Regulation of Complement cascade
  • Complement cascade
  • G alpha (i) signalling events
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Adaptive Immune System
  • Innate Immune System
  • Axon guidance
  • Laminin interactions
  • ECM proteoglycans
  • L1CAM interactions
  • Non-integrin membrane-ECM interactions
C3 and CR2 complement component 3 complement component (3d/Epstein Barr virus) receptor 2
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • Alternative complement activation
  • Class A/1 (Rhodopsin-like receptors)
  • Activation of C3 and C5
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Initial triggering of complement
  • GPCR downstream signaling
  • Peptide ligand-binding receptors
  • Regulation of Complement cascade
  • Complement cascade
  • G alpha (i) signalling events
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Adaptive Immune System
  • Innate Immune System
FMNL1 and HMG20A formin-like 1 high mobility group 20A
CA3 and SRC carbonic anhydrase III SRC proto-oncogene, non-receptor tyrosine kinase
  • Reversible hydration of carbon dioxide
  • Signaling by ERBB2
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
CACNA1A and ARHGAP22 calcium channel, voltage-dependent, P/Q type, alpha 1A subunit Rho GTPase activating protein 22
  • Integration of energy metabolism
  • Regulation of insulin secretion
  • Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels
  • Transmission across Chemical Synapses
  • Rho GTPase cycle
  • Signaling by Rho GTPases
  • Pregabalin
  • Verapamil
  • Loperamide
  • Bepridil
DDR1 and PTPN11 discoidin domain receptor tyrosine kinase 1 protein tyrosine phosphatase, non-receptor type 11
  • Non-integrin membrane-ECM interactions
  • Signaling by FGFR in disease
  • Netrin mediated repulsion signals
  • Signaling by EGFRvIII in Cancer
  • Interferon gamma signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Toll Like Receptor TLR1:TLR2 Cascade
  • PI3K/AKT activation
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Prolactin receptor signaling
  • SHC-mediated signalling
  • PI3K Cascade
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • ERK1 activation
  • Spry regulation of FGF signaling
  • Constitutive PI3K/AKT Signaling in Cancer
  • Platelet sensitization by LDL
  • Signaling by VEGF
  • Signalling to RAS
  • Toll Like Receptor 3 (TLR3) Cascade
  • Downstream signal transduction
  • Interleukin-2 signaling
  • PI3K/AKT Signaling in Cancer
  • Frs2-mediated activation
  • Adaptive Immune System
  • Axon guidance
  • IRS-mediated signalling
  • Interleukin-6 signaling
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • PI3K events in ERBB2 signaling
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • NCAM signaling for neurite out-growth
  • Netrin-1 signaling
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Signaling by Insulin receptor
  • Insulin receptor signalling cascade
  • Interferon Signaling
  • CTLA4 inhibitory signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • Tie2 Signaling
  • PECAM1 interactions
  • Signaling by FGFR
  • ARMS-mediated activation
  • Nuclear signaling by ERBB4
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • PD-1 signaling
  • PI3K Cascade
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • FCERI mediated MAPK activation
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • DAP12 signaling
  • PI-3K cascade
  • Toll Like Receptor 9 (TLR9) Cascade
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • Regulation of IFNA signaling
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • SHC-related events triggered by IGF1R
  • Signal regulatory protein (SIRP) family interactions
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Platelet homeostasis
  • Toll Like Receptor 4 (TLR4) Cascade
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-3, 5 and GM-CSF signaling
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Costimulation by the CD28 family
  • ERK activation
  • PIP3 activates AKT signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • IRS-related events triggered by IGF1R
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Interferon alpha/beta signaling
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • MyD88-independent cascade
  • Cell surface interactions at the vascular wall
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • FRS2-mediated cascade
  • ERK2 activation
  • Regulation of IFNG signaling
  • Imatinib
  • Dodecane-Trimethylamine
CALM1 and INSR calmodulin 1 (phosphorylase kinase, delta) insulin receptor
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Insulin receptor signalling cascade
  • IRS activation
  • Signal attenuation
  • IRS-related events
  • SHC-related events
  • Insulin receptor recycling
  • SHC activation
  • Signaling by Insulin receptor
  • Insulin Regular
  • Insulin Lispro
  • Insulin Glargine
  • Insulin, porcine
  • Mecasermin
  • Insulin Aspart
  • Insulin Detemir
  • Insulin Glulisine
  • Adenosine-5\'-[Beta, Gamma-Methylene]Triphosphate
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • Insulin, isophane
CALM1 and RRAD calmodulin 1 (phosphorylase kinase, delta) Ras-related associated with diabetes
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization

Page 43 out of 155 pages